Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Devextinetug - InterveXion Therapeutics

Drug Profile

Devextinetug - InterveXion Therapeutics

Alternative Names: Anti-methamphetamine chimeric monoclonal antibody - InterveXion Therapeutics; Anti-methamphetamine monoclonal antibody; Ch-mAb7F9; IXT-m200; METH-mAb

Latest Information Update: 19 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Arkansas for Medical Sciences
  • Developer InterveXion Therapeutics
  • Class Drug withdrawal therapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Substance-related disorders

Most Recent Events

  • 05 Jan 2023 InterveXion Therapeutics terminates a phase II Meth-OD trial in Substance-related disorders in USA (IV) (NCT04715230)
  • 25 Apr 2022 InterveXion Therapeutics and the National Institute on Drug Abuse initiates a phase II trial in Substance related disorders in USA (IV) (NCT05034874)
  • 18 Mar 2022 InterveXion Therapeutics and the National Institute on Drug Abuse completed the phase I trial in Substance related disorders (In volunteers) in USA (IV) (NCT05027451)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top